NEW HAVEN, Conn., Aug. 12, 2008 (PRIME NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced that Michael D. Kishbauch, President and Chief Executive Officer of Achillion, will be presenting a corporate overview and update on the Company’s programs in HIV, HCV and serious bacterial infections at the Canaccord Adams 28th Annual Global Growth Conference on Wednesday, August 13, 2008 at 4:30 p.m. at the InterContinental Hotel in Boston.
